Biosimilar Code Blending By CMS Could Cause Tracking, Payment Problems
This article was originally published in The Pink Sheet Daily
Rivals Sandoz and Amgen both say CMS decision on J-codes removes feature for tracking adverse events.
You may also be interested in...
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.
Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.